We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Companies line up for hereditary angioedema market.
- Authors
Huggett, Brady
- Abstract
The article reports on several companies which are vying for the approval of the U.S. Food and Drug Administration (FDA) for their hereditary angioedema (HAE) therapeutics. They include Jerini AG, which has the advantage of receiving the first decision from FDA for its licensed drug Icatibant, and Dyax Corp. for its DX-88 recombinant small protein. Other participating companies are Pharming for Rhucin, CSL Behring for Berinert, and Lev for Cinryze. Meanwhile, HAE refers to a disease caused by low serum levels of C1 esterase inhibitor.
- Subjects
UNITED States; ANGIONEUROTIC edema; JERINI AG; DYAX Corp.; PHARMING Group NV; CSL Behring LLC; LEV (Company); UNITED States. Food &; Drug Administration; PHARMACEUTICAL industry; THERAPEUTICS
- Publication
Nature Biotechnology, 2008, Vol 26, Issue 4, p364
- ISSN
1087-0156
- Publication type
Article
- DOI
10.1038/nbt0408-364